This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

signup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 4

Based on the information you provided, we found the following studies.

  • A First-In-Human Study of Dosing with REGN2810 as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies Study purpose: find safe dose of REGN2810 given alone or in combination therapies;measure levels of REGN2810 in blood; evaluate if REGN2810 given alone or in combination w/other therapies will cause tumor shrinkage;test different dose levels of REGN2810, radiotherapy, GM-CSF, and cyclophosphamide. This study is researching all of the following topics: Bladder cancer Breast cancer Cervical cancer Colorectal / Colon / Rectal cancer Esophagus cancer HCC, Liver cancer Kidney Cancer ( Malignant tumor of kidney ) Laryngeal cancer, Cancer of the larynx, Voice box cancer Lung cancer Oral / Mouth cancer Ovarian cancer Pancreatic cancer Prostate cancer Stomach cancer, Gastric cancer ( Malignant tumor of stomach ) Thyroid cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase II study of ponatinib for advanced cancers with genomic alterations in fibroblastic growth factor receptor (FGFR) and other genomic targets (KIT, PDGFRa, RET FLT3, ABL1) The purpose of this study is to find out what effects; good and/or bad, ponatinib has on you and your cancer. Your body has proteins that are involved in a cancer’s ability to grow and survive. The drug, Ponatinib, may prevent these proteins from causing cancer growth. This study is researching all of the following topics: Bladder cancer Breast cancer Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Esophagus cancer Kidney Cancer ( Malignant tumor of kidney ) Lung cancer Ovarian cancer Pancreatic cancer Prostate cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I safety study of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies This study is being done to learn whether treatment with Clostridium novyi-NT spores (NT refers to non-toxin producing) is safe and effective in patients with advanced cancers that can no longer be controlled with standard therapy or cancers for which there is no standard effective treatment. This study is researching all of the following topics: Adrenal cancer BCC, Basal cell skin cancer Bladder cancer Bone cancer Breast cancer Cervical cancer Colon Cancer ( Malignant tumor of colon ) Esophagus cancer Fallopian tube cancer HCC, Liver cancer Kidney Cancer ( Malignant tumor of kidney ) Laryngeal cancer, Cancer of the larynx, Voice box cancer Lung cancer Lymphoma NPC, Nasal cancer Oral / Mouth cancer Ovarian cancer Pancreatic cancer Prostate cancer Salivary Gland Cancer Sarcoma Squamous cell skin cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Pioglitazone in metastatic thyroid cancer Through this trial we hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by This study is researching all of the following topics: Thyroid cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • 18 years to 75 years